APH vs ZYME · P/E 40, rev $23.09B vs rev $76.3M
Amphenol Corporation (APH) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
APH currently screens at market cap $170.77B and trailing P/E 39.9. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the APH and ZYME stock pages for the full models.
Not investment advice.